| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Department of Oncology, Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, New York;
2 School of Public Health, New York Medical College, Valhalla, New York;
3 Biostatistics Unit, North Shore-Long Island Jewish Research Institute, Manhasset, New York; and
4 Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
5-Fluorouracil (5-FU) is the most common chemotherapeutic agent used in the treatment of colorectal cancer, yet objective response rates are low. Recently, camptothecin (CPT) has emerged as an effective alternative therapy. Decisive means to determine treatment, based on the likelihood of response to each of these agents, could greatly enhance the management of this disease. Here, the ability of cDNA microarray-generated basal gene expression profiles to predict apoptotic response to 5-FU and CPT was determined in a panel of 30 colon carcinoma cell lines. Genes whose basal level of expression correlated significantly with 5-FU- and CPT-induced apoptosis were selected, and their predictive power was assessed using a "leave one out" jackknife cross-validation strategy. Selection of the 50 genes best correlated with 5-FU-induced apoptosis, but not 50 randomly selected genes, significantly predicted response to this agent. Importantly, this gene expression profiling approach predicted response more effectively than four previously established determinants of 5-FU response: thymidylate synthase and thymidine phosphorylase activity; and p53 and mismatch repair status. Furthermore, reanalysis of the database demonstrated that selection of the 149 genes best correlated with CPT-induced apoptosis maximally and significantly predicted response to this agent. These studies demonstrate that the basal gene expression profile of colon cancer cells can be used to predict and distinguish response to multiple chemotherapeutic agents and establish the potential of this methodology as a means by which rational decisions regarding choice of therapy can be approached.
This article has been cited by other articles:
![]() |
T. Uemura, H. F. Yerushalmi, G. Tsaprailis, D. E. Stringer, K. E. Pastorian, L. Hawel III, C. V. Byus, and E. W. Gerner Identification and Characterization of a Diamine Exporter in Colon Epithelial Cells J. Biol. Chem., September 26, 2008; 283(39): 26428 - 26435. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Pezo, S. J. Gandhi, L. A. Shirley, R. G. Pestell, L. H. Augenlicht, and R. H. Singer Single-Cell Transcription Site Activation Predicts Chemotherapy Response in Human Colorectal Tumors Cancer Res., July 1, 2008; 68(13): 4977 - 4982. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jhawer, S. Goel, A. J. Wilson, C. Montagna, Y.-H. Ling, D.-S. Byun, S. Nasser, D. Arango, J. Shin, L. Klampfer, et al. PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab Cancer Res., March 15, 2008; 68(6): 1953 - 1961. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Laguinge, R. N. Samara, W. Wang, W. S. El-Deiry, G. Corner, L. Augenlicht, L. Mishra, and J. M. Jessup DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines Cancer Res., February 1, 2008; 68(3): 909 - 917. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Sagiv, U. Rozovski, D. Kazanov, E. Liberman, and N. Arber Gene Expression Analysis Proposes Alternative Pathways for the Mechanism by Which Celecoxib Selectively Inhibits the Growth of Transformed but not Normal Enterocytes Clin. Cancer Res., November 15, 2007; 13(22): 6807 - 6815. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Sekine, J. D. Minna, K. Nishio, N. Saijo, and T. Tamura Genes Regulating the Sensitivity of Solid Tumor Cell Lines to Cytotoxic Agents: A Literature Review Jpn. J. Clin. Oncol., May 1, 2007; 37(5): 329 - 336. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. H. Jensen, J. M. Lewis, J. M. McLoughlin, M. D. Alvarado, A. Daud, J. Messina, S. Enkemann, T. J. Yeatman, V. K. Sondak, and A. I. Riker Down-Regulation of Pro-Apoptotic Genes is an Early Event in the Progression of Malignant Melanoma Ann. Surg. Oncol., April 1, 2007; 14(4): 1416 - 1423. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Del Rio, F. Molina, C. Bascoul-Mollevi, V. Copois, F. Bibeau, P. Chalbos, C. Bareil, A. Kramar, N. Salvetat, C. Fraslon, et al. Gene Expression Signature in Advanced Colorectal Cancer Patients Select Drugs and Response for the Use of Leucovorin, Fluorouracil, and Irinotecan J. Clin. Oncol., March 1, 2007; 25(7): 773 - 780. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Huang, K. Reeves, X. Han, C. Fairchild, S. Platero, T. W. Wong, F. Lee, P. Shaw, and E. Clark Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection Cancer Res., March 1, 2007; 67(5): 2226 - 2238. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Grade, P. Hormann, S. Becker, A. B. Hummon, D. Wangsa, S. Varma, R. Simon, T. Liersch, H. Becker, M. J. Difilippantonio, et al. Gene Expression Profiling Reveals a Massive, Aneuploidy-Dependent Transcriptional Deregulation and Distinct Differences between Lymph Node-Negative and Lymph Node-Positive Colon Carcinomas Cancer Res., January 1, 2007; 67(1): 41 - 56. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Davalos, H. Dopeso, J. Castano, A. J. Wilson, F. Vilardell, J. Romero-Gimenez, E. Espin, M. Armengol, G. Capella, J. M. Mariadason, et al. EPHB4 and Survival of Colorectal Cancer Patients. Cancer Res., September 15, 2006; 66(18): 8943 - 8948. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Wilson, D.-S. Byun, N. Popova, L. B. Murray, K. L'Italien, Y. Sowa, D. Arango, A. Velcich, L. H. Augenlicht, and J. M. Mariadason Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer J. Biol. Chem., May 12, 2006; 281(19): 13548 - 13558. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Fan, M. Zhan, J. Shen, J. L. Martindale, X. Yang, T. Kawai, and M. Gorospe En masse nascent transcription analysis to elucidate regulatory transcription factors Nucleic Acids Res., March 15, 2006; 34(5): 1492 - 1500. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Boyer, W. L. Allen, E. G. McLean, P. M. Wilson, A. McCulla, S. Moore, D. B. Longley, C. Caldas, and P. G. Johnston Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res., March 1, 2006; 66(5): 2765 - 2777. [Abstract] [Full Text] [PDF] |
||||
![]() |
I.-J. Kim, H. C. Kang, S.-G. Jang, K. Kim, S.-A Ahn, H.-J. Yoon, S. N. Yoon, and J.-G. Park Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations Carcinogenesis, March 1, 2006; 27(3): 392 - 404. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Chowdary, J. Lathrop, J. Skelton, K. Curtin, T. Briggs, Y. Zhang, J. Yu, Y. Wang, and A. Mazumder Prognostic Gene Expression Signatures Can Be Measured in Tissues Collected in RNAlater Preservative J. Mol. Diagn., February 1, 2006; 8(1): 31 - 39. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Alazzouzi, V. Davalos, A. Kokko, E. Domingo, S. M. Woerner, A. J. Wilson, L. Konrad, P. Laiho, E. Espin, M. Armengol, et al. Mechanisms of Inactivation of the Receptor Tyrosine Kinase EPHB2 in Colorectal Tumors Cancer Res., November 15, 2005; 65(22): 10170 - 10173. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Alhopuro, H. Alazzouzi, H. Sammalkorpi, V. Davalos, R. Salovaara, A. Hemminki, H. Jarvinen, J.-P. Mecklin, S. Schwartz Jr., L. A. Aaltonen, et al. SMAD4 Levels and Response to 5-Fluorouracil in Colorectal Cancer Clin. Cancer Res., September 1, 2005; 11(17): 6311 - 6316. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. L. Allen and P. G. Johnston Role of Genomic Markers in Colorectal Cancer Treatment J. Clin. Oncol., July 10, 2005; 23(20): 4545 - 4552. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Perathoner, D. Pirkebner, G. Brandacher, G. Spizzo, S. Stadlmann, P. Obrist, R. Margreiter, and A. Amberger 14-3-3{sigma} Expression Is an Independent Prognostic Parameter for Poor Survival in Colorectal Carcinoma Patients Clin. Cancer Res., May 1, 2005; 11(9): 3274 - 3279. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Ghadimi, M. Grade, M. J. Difilippantonio, S. Varma, R. Simon, C. Montagna, L. Fuzesi, C. Langer, H. Becker, T. Liersch, et al. Effectiveness of Gene Expression Profiling for Response Prediction of Rectal Adenocarcinomas to Preoperative Chemoradiotherapy J. Clin. Oncol., March 20, 2005; 23(9): 1826 - 1838. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Andersen, T. Heine, R. Sneve, I. Konig, H. E. Krokan, B. Epe, and H. Nilsen Incorporation of dUMP into DNA is a major source of spontaneous DNA damage, while excision of uracil is not required for cytotoxicity of fluoropyrimidines in mouse embryonic fibroblasts Carcinogenesis, March 1, 2005; 26(3): 547 - 555. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Chan and D. J. Kerr Can we individualise chemotherapy for colorectal cancer? Ann. Onc., July 1, 2004; 15(7): 996 - 999. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |